Low levels of activated factor VII in systemic sclerosis

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 2, 2006, Pages 133-138

  Volpe, Alessandro ^a   Salvagno, Gian Luca ^a   Lippi, Giuseppe ^a   Caramaschi, Paola ^a   Montagnana, Martina ^a   Canestrini, Sabrina ^a   Carletto, Antonio ^a   Bambara, Lisa Maria ^a   Biasi, Domenico ^a   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Activated factor VII; Coagulation; Systemic sclerosis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 7A; CYCLOPHOSPHAMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; PREDNISONE; VASODILATOR AGENT;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; ISCHEMIA; KIDNEY FUNCTION; LUNG DISEASE; MALE; MEDICAL INSTRUMENTATION; MICROANGIOPATHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCLERODERMA; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ADULT; AGED; CASE-CONTROL STUDIES; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 33749171384     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-8969-8     Document Type: Article

References (39)

1. Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718-722
2. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603-610
3. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, et al (2003) Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63:2997-3000
4. James NJ, Ettelaie C, Bruckdorfer KR (2002) Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogenesis. Biochem Soc Trans 30:217-221
5. Pendurthi UR, Rao LV (2002) Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. Vitam Horm 64:323-355
6. Cirillo P, Cali G, Golino P, Calabro P, Forte L, De Rosa S et al (2004) Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109:2911-2916
7. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC (2003) Antiapoptotic effect of coagulation factor VIIa. Blood 102:1708-1715
8. Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC et al (1998) Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 273:6228-6232
9. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734-744
10. Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH, Ronnstrand L (2000) Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96:3452-3458
11. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
12. LeRoy EC, Fleischmajer R, Black CM, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-205
13. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S et al (2001) European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592-598
14. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR (2002) Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 21(suppl 29):S5-S8
15. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(suppl 29):S42-S46
16. Cutolo M, Grassi W, Matucci Cerinic M (2003) Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023-3030
17. Versteeg HH, Peppelenbosch MP, Spek CA (2001) The pleiotropic effects of tissue factor: A possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 86:1353-1359
18. Nawroth PP, Handley DA, Esmon CT, Stern DM (1986) Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460-3465
19. Colucci, M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al (1983) Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71:1893-1896
20. Golino, P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N et al (1996) Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 2:35-41
21. Golino P, Ragni M, Cirillo P, Scognamiglio A, Ravera A, Buono C et al (2000) Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol 278:H1507-H1516
22. Hoffman M, Monroe DM 3rd (2001) The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 38:6-9
23. Wilcox JN, Smith KM, Schwartz SM, Gordon D (1989) Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86:2839-2843
24. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR et al (1986) Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet. 2:533-537
25. Romisch J (2002) Factor VII activating protease (FSAP): A novel protease in hemostasis. Biol Chem 383:1119-1124
26. Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L et al (1997) The coagulation/fibrinolysis balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br J Rheumatol 36:1045-1050
27. Matucci-Cerinic M, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285-295
28. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11
29. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275-3285
30. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889-893
31. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785-792
32. Nguyen VA, Sgonc R, Dietrich H, Wick G (2000) Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). J Autoimmun 14:143-149
33. Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y et al (2005) Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J Immunol 174:5740-5749
34. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550-2562
35. Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME et al (2003) In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 48: 2605-2614
36. Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6: 1183-1186
37. Barnett JM, Demel KC, Mega AE, Butera JN, Sweeney JD (2005) Lack of bleeding in patients with severe factor VII deficiency. Am J Hematol 78:134-137
38. Escoffre M, Zini JM, Schliamser L, Mazoyer E, Soria C, Tobelem G et al (1995) Severe arterial thrombosis in a congenitally factor VII deficient patient. Br J Haematol 91:739-741
39. Biron C, Bengler C, Gris JC, Schved JF (1997) Acquired isolated factor VII deficiency during sepsis. Haemostasis 27:51-56